Top news of the week: 09.06.2020.
#COVID19 #COVID__19 #BIODigital #BeyondImagination #biotechnews #MS
Healthcare
RT @lisamjarvis: Read (or listen). And after, thank @TonyColesMD for being willing to share his immense wisdom and so graciously speaking on such a personal level in order to educate the biotech community, which (like the rest of society) has so much work to do: https://t.co/aGQg9h4k7w
OpenLongtime executive Tony Coles on biotech, racism, and opportunities for change
The biotech executive spoke with STAT about global action after George Floyd’s killing, parsing pharma statements, and how executives can combat racism.
RT @HelenBranswell: What could @TheLancet & @NEJM have done better to prevent the kinds of problems that led to last week's retractions of 2 high-profile #Covid19 papers? @sxbegle explores. https://t.co/3jk05BQeyX
OpenAfter retractions of two Covid-19 papers, scientists ask what went wrong
After the retractions of two Covid-19 papers from top journals, the scientific community is once again wrestling whether it could have been prevented.
RT @adamfeuerstein: Moderna released scant #COVID19 data to prevent a leak, CEO says https://t.co/K00MPtEhYe via @damiangarde $MRNA
OpenModerna released scant Covid-19 data to prevent a leak, CEO says
Stéphane Bancel, the company’s CEO, said Moderna’s decision to be vague was a matter of respecting securities laws and the rules of scientific journals.
GSK's cell therapy R&D lead jumps ship to partner Immatics https://t.co/u7pFyncvet https://t.co/HwVVfuO8GV
OpenGSK's cell therapy R&D lead jumps ship to partner Immatics
Just a few months after GlaxoSmithKline penned a $50 million deal with biotech Immatics for its T-cell work, the executive running the Big Pharma’s cancer cell therapy unit is upping sticks ...
RT @IAmBiotech: Our newest #BeyondImagination feature at @BIOConvention’s #BIODigital highlights @Alnylam and its work on RNAi therapeutics that target cells directly to treat the root-genetic cause of disease rather than only its symptoms. https://t.co/h6bwP7m5Wg https://t.co/OjhnnVRpCo
OpenTargeting “Undruggable” Diseases
Our series, Biotechnology: Beyond Imagination, highlights the technology and scientific advancements of BIO Digital participating companies and BIO member companies. Our next feature looks ...
RT @BiotechSweden: After Kaletra setback, AbbVie joins forces with biotech, academia for experimental COVID-19 hopeful https://t.co/5ZQFOpTvCz
OpenAfter Kaletra setback, AbbVie joins forces with biotech, academia for experimental COVID-19 hopeful
Earlier this year, AbbVie tried and stumbled in a clinical trial using its HIV med Kaletra to help certain COVID-19 patients; now, it’s tapping a triumvirate of life science groups to ...
RT @lydiaramsey125: The Lancet just put out a warning about the massive observational hydroxychloroquine study it published in May
https://t.co/RFjzen5Hmv
OpenEditors warn that 'serious scientific questions' have been raised about a massive study of whether a common malaria pill can help treat coronavirus
The massive study of 96,032 hospitalized coronavirus patients found that hydroxychloroquine did not appear to benefit the patients who took it.
The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) Agenus Inc (NASDAQ: AGEN)(...